Clinical Trial Update: A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating paclitaxel and topotecan with Filgrastim-SD/01 support in relapsed and refractory aggressive non-Hodgkin's lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Filgrastim-SD/01 (filgrastim)
• PACLITAXEL (PACLITAXEL)
• Topotecan (topotecan)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED